FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 35 filers reported holding FUSION PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $639,694 | -44.3% | 246,036 | 0.0% | 0.20% | -32.2% |
| Q2 2023 | $1,148,988 | +23.9% | 246,036 | 0.0% | 0.29% | -36.4% |
| Q1 2023 | $927,556 | +13.1% | 246,036 | -5.5% | 0.46% | +51.5% |
| Q4 2022 | $820,411 | +4.6% | 260,448 | 0.0% | 0.30% | +21.7% |
| Q3 2022 | $784,000 | +20.8% | 260,448 | 0.0% | 0.25% | +2.0% |
| Q2 2022 | $649,000 | -67.8% | 260,448 | +0.3% | 0.24% | -63.5% |
| Q1 2022 | $2,018,000 | +86.3% | 259,763 | 0.0% | 0.67% | +104.9% |
| Q4 2021 | $1,083,000 | -47.4% | 259,763 | 0.0% | 0.33% | -50.3% |
| Q3 2021 | $2,057,000 | -4.3% | 259,763 | -2.4% | 0.66% | +22.8% |
| Q2 2021 | $2,150,000 | -19.6% | 266,107 | +6.7% | 0.53% | -1.7% |
| Q1 2021 | $2,674,000 | +31.8% | 249,419 | +44.4% | 0.54% | +30.8% |
| Q4 2020 | $2,029,000 | +3801.9% | 172,693 | +5656.4% | 0.42% | +2666.7% |
| Q2 2020 | $52,000 | – | 3,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ADAMS STREET PARTNERS LLC | 2,973,744 | $24,028,000 | 4.99% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,598,377 | $12,613,000 | 4.97% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,670,516 | $29,658,000 | 3.03% |
| Sio Capital Management, LLC | 266,107 | $2,150,000 | 0.53% |
| Orbimed Advisors | 3,224,770 | $26,056,000 | 0.26% |
| Perceptive Advisors | 3,550,334 | $28,686,000 | 0.19% |
| AlphaCentric Advisors LLC | 71,500 | $578,000 | 0.16% |
| Rock Springs Capital Management LP | 948,327 | $7,662,000 | 0.15% |
| TPG Group Holdings (SBS) Advisors, Inc. | 2,551,794 | $20,618,000 | 0.15% |
| Artal Group S.A. | 750,000 | $6,060,000 | 0.12% |